Jason E. Comer
University of Texas Medical Branch
39 Papers
433 Citations
Jason E. Comer is an academic researcher from University of Texas Medical Branch. The author has contributed to research in topics: Ebola virus & Medicine. The author has an hindex of 15, co-authored 31 publications.
Chat about Author
Papers
Direct Inhibition of T-Lymphocyte Activation by Anthrax Toxins In Vivo
TL;DR: It is shown that injection of sublethal doses of either lethal or edema toxin into mice directly inhibited the subsequent activation of T lymphocytes by T-cell receptor-mediated stimulation, important for future anthrax vaccine development and treatment.
115
Human Monoclonal Anti-Protective Antigen Antibody Completely Protects Rabbits and Is Synergistic with Ciprofloxacin in Protecting Mice and Guinea Pigs against Inhalation Anthrax
Johnny W. Peterson,Jason E. Comer,David M. Noffsinger,Autumn Wenglikowski,Kristin G. Walberg,Bagram M. Chatuev,Ashok K. Chopra,Lawrence R. Stanberry,Angray S. Kang,Wolfgang W. Scholz,Jagadish Sircar +10 more
TL;DR: The effectiveness of human anti-PA antibody alone or in combination with low ciprofloxacin levels may provide the basis for an improved strategy for prophylaxis or treatment following inhalation anthrax infection.
94
Plasmodium Ookinete-secreted Proteins Secreted through a Common Micronemal Pathway Are Targets of Blocking Malaria Transmission
Fengwu Li,Thomas J. Templeton,Vsevolod L. Popov,Jason E. Comer,Takafumi Tsuboi,Motomi Torii,Joseph M. Vinetz +6 more
TL;DR: Results support the concept that ookinete micronemal proteins may constitute a general class of malaria transmission-blocking vaccine candidates.
76
Immunogenicity and Efficacy of a Measles Virus-Vectored Chikungunya Vaccine in Nonhuman Primates.
Shannan L. Rossi,Jason E. Comer,Eryu Wang,Sasha R. Azar,William S Lawrence,Jessica A. Plante,Katrin Ramsauer,Sabrina Schrauf,Scott C. Weaver +8 more
TL;DR: These results further document the immunogenicity and efficacy of a measles-vectored chikungunya vaccine that shows promise in Phase I–II clinical trials and are critical to human health because no vaccine to combat CHIKF is yet licensed.
62
Human Monoclonal Antibody AVP-21D9 to Protective Antigen Reduces Dissemination of the Bacillus anthracis Ames Strain from the Lungs in a Rabbit Model
Johnny W. Peterson,Jason E. Comer,Wallace B. Baze,David M. Noffsinger,Autumn Wenglikowski,Kristin G. Walberg,Jason Hardcastle,Jennifer Pawlik,Kathryn Bush,Joanna Taormina,Scott T. Moen,John A. Thomas,Bagram M. Chatuev,Laurie E. Sower,Ashok K. Chopra,Lawrence R. Stanberry,Ritsuko Sawada,Wolfgang Scholz,Jagadish Sircar +18 more
TL;DR: AVP-21D9 completely protected both rabbit strains against lethal infection with Bacillus anthracis Ames spores, regardless of the inoculation method, and could offer an adjunct or alternative clinical treatment regimen against inhalation anthrax.
60